DIRECT COST ANALYSIS AND COST EFFECTIVENESS ANALYSIS OF CHRONIC OBSTRUCTION PULMONARY DISEASE IN FATMAWATI PUBLIC HOSPITAL
Author(s)
Anwar Y1, Afdhal AF1, Anggraini Y2
117 August 1945 Jakarta University, Jakarta, Indonesia, 2Pancasila University, Jakarta, Indonesia
Presentation Documents
OBJECTIVES: Chronic Obstruction Pulmonary Disease (COPD) is one of the world causes of morbidity and mortality. Level of COPD seriousness results in the increasing number of Length Of Stay(LOS) in the hospital. This research has been conducted in 2014 to analyse total direct cost and cost effectiveness analysis by the combination of ipratropium and salbutamol and single salbutamol on the COPD in Fatmawati Public Hospital Jakarta. METHODS: COPD patients who were hospitalized in Fatmawati Public Hospital between 1 January 2010 – 31 March 2014 were grouped according to the classification of COPD by Indonesian Pulmonary Doctor Association. Study design used was cross sectionaland retrospective. In addition, data were analyzed descriptively and calculating the Pearson correlation (r) that was conducted on the seriousness level of COPD on total direct cost. In addition, cost effectiveness of the combination of ipratropium and salbutamol therapy was compared to single salbutamol therapy on COPD patients. RESULTS: Among 237 patients of COPD, 122 patients with primary diagnosis and 115 patients with accompanying diagnosis. There were 97 patients who met inclusion criteria. The average total direct costs were IDR15,069,927.23. The highest cost was on cost of hospital stay, IDR5,106,409.99 (35,32%), followed by medicament cost IDR4,984,922.86 (32,51%). There was a very strong correlation (r = 0.876) between COPD seriousness level with the average direct total costs per year with or without comorbidity. COPD therapy, It has also shown, that cost and effectiveness were not significantly differed (p > 0.05) between salbutamol combination and single salbutamol. CONCLUSIONS: In primary care, disease management should more focused on the holistic assessment and reduction of symptoms. For the future purposes treatment of COPD should follow the published guidelines for systematic diagnosis of symptoms and health status. This is important to improve the clinical outcome of individual and patients.
Conference/Value in Health Info
2016-09, ISPOR Asia Pacific 2016, Singapore
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PRS7
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies, Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Respiratory-Related Disorders